Størset Elisabet, Åsberg Anders, Skauby Morten, Neely Michael, Bergan Stein, Bremer Sara, Midtvedt Karsten
1 Department of Transplant Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway. 2 Institute of Clinical Medicine, University of Oslo, Oslo, Norway. 3 School of Pharmacy, University of Oslo, Oslo, Norway. 4 Laboratory of Applied Pharmacokinetics, Children's Hospital Los Angeles, Los Angeles, CA. 5 Department of Pharmacology, Oslo University Hospital, Oslo, Norway. 6 Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway.
Transplantation. 2015 Oct;99(10):2158-66. doi: 10.1097/TP.0000000000000708.
Early after renal transplantation, it is often challenging to achieve and maintain tacrolimus concentrations within the target range. Computerized dose individualization using population pharmacokinetic models may be helpful. The objective of this study was to prospectively evaluate the target concentration achievement of tacrolimus using computerized dosing compared with conventional dosing performed by experienced transplant physicians.
A single-center, prospective study was conducted. Renal transplant recipients were randomized to receive either computerized or conventional tacrolimus dosing during the first 8 weeks after transplantation. The median proportion of tacrolimus trough concentrations within the target range was compared between the groups. Standard risk (target, 3-7 μg/L) and high-risk (8-12 μg/L) recipients were analyzed separately.
Eighty renal transplant recipients were randomized, and 78 were included in the analysis (computerized dosing (n = 39): 32 standard risk/7 high-risk, conventional dosing (n = 39): 35 standard risk/4 high-risk). A total of 1711 tacrolimus whole blood concentrations were evaluated. The proportion of concentrations per patient within the target range was significantly higher with computerized dosing than with conventional dosing, both in standard risk patients (medians, 90% [95% confidence interval {95% CI}, 84-95%] vs 78% [95% CI, 76-82%], respectively, P < 0.001) and in high-risk patients (medians, 77% [95% CI, 71-80%] vs 59% [95% CI, 40-74%], respectively, P = 0.04).
Computerized dose individualization improves target concentration achievement of tacrolimus after renal transplantation. The computer software is applicable as a clinical dosing tool to optimize tacrolimus exposure and may potentially improve long-term outcome.
肾移植术后早期,将他克莫司浓度维持在目标范围内往往具有挑战性。使用群体药代动力学模型进行计算机化剂量个体化可能会有所帮助。本研究的目的是前瞻性评估与经验丰富的移植医生进行的传统给药相比,使用计算机化给药时他克莫司的目标浓度达成情况。
进行了一项单中心前瞻性研究。肾移植受者在移植后的前8周被随机分配接受计算机化或传统的他克莫司给药。比较两组中他克莫司谷浓度在目标范围内的中位数比例。分别对标准风险(目标值为3 - 7μg/L)和高风险(8 - 12μg/L)受者进行分析。
80名肾移植受者被随机分组,78名纳入分析(计算机化给药组(n = 39):32名标准风险/7名高风险;传统给药组(n = 39):35名标准风险/4名高风险)。共评估了1711次他克莫司全血浓度。在标准风险患者中,计算机化给药时每位患者在目标范围内的浓度比例显著高于传统给药(中位数分别为90% [95%置信区间{95%CI},84 - 95%] 对78% [95%CI,76 - 82%],P < 0.001);在高风险患者中也是如此(中位数分别为77% [95%CI,71 - 80%] 对59% [95%CI,40 - 74%],P = 0.04)。
计算机化剂量个体化可提高肾移植术后他克莫司的目标浓度达成情况。该计算机软件可作为一种临床给药工具来优化他克莫司的暴露量,并可能潜在地改善长期预后。